Friday, January 20, 2023 3:31:00 PM
Biosect,
I believe practically every trial sponsored by a company has someone from the company named in the clinical trials database as coordinating the trial from the company. In our case this person is Dr. Bosch. My point is that this person will be part of all that's released about trial results by anyone as a participant in most anything released about the trial, including Journal publications.
If I'm right about this, H-G's or anyone else's claim that that person brings a bias into publications, presentations, etc. is something that can be said for practically all such things. Such people may not be involved if the company has no sponsorship in the trial, like the ones being done at UCLA, but I believe that nearly all Phase 3 Trials have corporate sponsors.
Like so many of H-G's claims, what NWBO is doing is no different than what nearly every biotech or BP does when it comes to bringing a product to approval. Certainly some companies, especially those with unlimited funds, may do it faster, but nonetheless it gets done.
Gary
I believe practically every trial sponsored by a company has someone from the company named in the clinical trials database as coordinating the trial from the company. In our case this person is Dr. Bosch. My point is that this person will be part of all that's released about trial results by anyone as a participant in most anything released about the trial, including Journal publications.
If I'm right about this, H-G's or anyone else's claim that that person brings a bias into publications, presentations, etc. is something that can be said for practically all such things. Such people may not be involved if the company has no sponsorship in the trial, like the ones being done at UCLA, but I believe that nearly all Phase 3 Trials have corporate sponsors.
Like so many of H-G's claims, what NWBO is doing is no different than what nearly every biotech or BP does when it comes to bringing a product to approval. Certainly some companies, especially those with unlimited funds, may do it faster, but nonetheless it gets done.
Gary
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
